Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity

Background This trial evaluated the maximum tolerated dose (MTD), safety, pharmacokinetics, and activity of volasertib, a selective Polo-like kinase 1 inhibitor that induces mitotic arrest and apoptosis, combined with cisplatin or carboplatin in patients with advanced/metastatic solid tumors (NCT009...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Awada, Ahmad, Dumez, Herlinde, Aftimos, Philippe G., Costermans, Jo, Bartholomeus, Sylvie, Forceville, Kathleen, Berghmans, Thierry, Meeus, Marie-Anne, Cescutti, Jessica, Munzert, Gerd, Pilz, Korinna, Liu, Dan, Schöffski, Patrick
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2015
Assuntos:
Phase I Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4435638/
https://ncbi.nlm.nih.gov/pubmed/25794535
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0223-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados